Compositions and methods of treating pulmonary hypertension
AssigneeGilead Sciences, Inc.
InventorsLuiz Belardinelli, Hunter Campbell Gillies, Faquan Liang, John Shryock, Suya Yang
Life of this patent
Estimating the term…
Abstract
Provided are formulations comprising therapeutically effective amounts of ambrisentan or a pharmaceutically acceptable salt thereof and tadalafil or a pharmaceutically acceptable salt thereof and methods of treating and/or preventing pulmonary hypertension by administration of the formulations.
Claims21
A combination therapy comprising:
- a therapeutically effective amount of a selective type-A endothelin receptor antagonist (ERA) selected from the group consisting of ambrisentan, sitaxsentan and pharmaceutically acceptable salts thereof, and
- a therapeutically effective amount of a phosphodiesterase type 5 (PDE5) inhibitor selected from the group consisting of sildenafil, tadalafil, vardenafil and pharmaceutically acceptable salts thereof,
- wherein the weight ratio of the selective type-A ERA and the PDE5 inhibitor is in a range from about 1:1 to about 1:10.
A method for treating pulmonary hypertension in a patient comprising administering to the patient a therapeutic amount of a selective type-A ERA selected from the group consisting of ambrisentan, sitaxsentan and pharmaceutically acceptable salts thereof in combination with a therapeutically effective amount of a PDE5 inhibitor selected from the group consisting of sildenafil, tadalafil, vardenafil and pharmaceutically acceptable salts thereof, wherein the weight ratio of the selective type-A ERA and the PDE5 inhibitor is in a range from about 1:1 to about 1:10.
-32. (canceled)
Dependencies are inferred from the claim text.